Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer

Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer is a phase 2/3, randomised interventional study registered as NCT07134218 by Changhai Hospital, with a registry enrolment figure of 180 participants, started 2025-10 and due to reach its primary completion in 2027-10. Interventions recorded: serplulimab、bevacizumab; neoadjuvant chemoradiation therapy. Conditions listed: Rectal Cancer. Primary outcome: The rate of cCR. Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma with immunohistochemistry results showing proficient mismatch repair (pMMR) or molecular testing results indicating microsatellite stability (MSS);". Sites: China. No results are recorded here; the registry entry is the source.